Back to search results

Diet Intervention for Chemotherapy-Induced Peripheral Neuropathy

This study is looking at whether a special diet, called LASO-3, can help cancer survivors who have chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage from chemotherapy that causes numbness, tingling, or pain in the hands or feet. The LASO-3 diet focuses on lower added sugar, higher fiber, and higher omega-3 fatty acids. Researchers believe that diet changes can reduce inflammation, which might help manage CIPN. You might be able to join if you are 18 or older, finished neurotoxic chemotherapy at least three months ago, and have moderate numbness and tingling. The study aims to enroll 50 participants to see if this diet intervention is practical and if people complete the program and report improvements.

Study design
This is an interventional study planning to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
You would provide blood samples, attend virtual health education sessions, and complete surveys. Your electronic health records would also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be measured at the beginning of the study and again at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07365007

A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment

Recruiting
NAAges 18+InterventionalSupportive care
University of Michigan Rogel Cancer Center
~50 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:Biospecimen CollectionEducational InterventionElectronic Health Record ReviewInterviewSurvey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recruitment of all participants (Feasibility)
Measured over Up to 2 years
+3 more outcomes measured

Conditions

Chemotherapy-Induced Peripheral Neuropathy
Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Chemotherapy-Induced Peripheral Neuropathy

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Robert Knoerl · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center

Who to contact

Robert Knoerl
[email protected]
734-764-8617
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years or older
At least three months since last receiving neurotoxic chemotherapy
Self-report moderate (≥ 2/4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™) Numbness and Tingling Severity Item in the last week
Speak/read English
Have access to the internet

Exclusion

Pre-existing peripheral neuropathy from any cause
Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period
Are enrolled in symptom management trials that may alter CIPN severity
High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis
Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation
Consuming an average three or more servings of fish per week and/or consuming fish oil capsules containing eicosapentaenoic acid (EPA)+ docosahexaenoic acid (DHA) daily or consuming flax oil capsules daily
Consuming an average of less than 5 servings of sweets, candy bars, chocolate, doughnuts, cookies, cakes, pie, brownies, ice cream, pastries, or sugar sweetened beverages (e.g., soda or coffee/tea) per week

What this trial measures

  • Recruitment of all participants (Feasibility)Up to 2 years

    Feasibility will be established if the following benchmark is met, recruitment of all participants within a two-year period (Demand). The observed recruitment rate will be estimated along with exact 80% confidence intervals (CIs).

  • Completion of baseline and 12-week patient-reported outcome measures (Feasibility)At baseline and 12 weeks

    Feasibility will be established if the following benchmark is met, ≥ 60% completion of baseline and 12-week patient-reported outcome measures. The observed retention rate will be estimated along with exact 80% CIs.

  • Percent of LASO-3 participants who attend at least 5 out of 8 intervention sessions (Feasibility)Up to 12 weeks

    Feasibility will be established if the following benchmark is met, ≥ 60% of LASO-3 participants attend at least 5 out of 8 intervention sessions (Implementation). The observed retention rate will be estimated along with exact 80% CIs.

  • Percent of LASO-3 participants who self-report adherence to dietary goals (Feasibility)Up to 24 weeks

    Feasibility will be established if the following benchmark is met, ≥ 60% of LASO-3 participants self-report adherence to dietary goals via VioScreen food frequency questionnaire and/or monthly adherence checklists (Practicality). The observed adherence rate will be estimated along with exact 80% CIs.